Edgewise Research Development from 2010 to 2026

EWTX Stock  USD 28.68  0.68  2.32%   
Edgewise Therapeutics Research Development yearly trend continues to be fairly stable with very little volatility. Research Development is likely to outpace its year average in 2026. During the period from 2010 to 2026, Edgewise Therapeutics Research Development regression line of annual values had r-squared of  0.61 and arithmetic mean of  39,237,197. View All Fundamentals
 
Research Development  
First Reported
2020-03-31
Previous Quarter
33.6 M
Current Value
37.5 M
Quarterly Volatility
12.1 M
 
Covid
 
Interest Hikes
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 30.2 M, Interest Income of 30.2 M or Depreciation And Amortization of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.08. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Edgewise Stock
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Edgewise Therapeutics over the last few years. It is Edgewise Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Edgewise Research Development Regression Statistics

Arithmetic Mean39,237,197
Geometric Mean18,817,761
Coefficient Of Variation135.62
Mean Deviation42,381,713
Median8,624,000
Standard Deviation53,215,359
Sample Variance2831.9T
Range144.7M
R-Value0.78
Mean Square Error1180.7T
R-Squared0.61
Significance0.0002
Slope8,224,657
Total Sum of Squares45310T

Edgewise Research Development History

2026153.3 M
2025146 M
2024127 M
202390.9 M
202216.6 M
202132.2 M
202014.8 M

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development146 M153.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.